Radiopharmaceuticals Market Will Generate Booming Growth Opportunities to 2032

The global radiopharmaceuticals market stands at US$ 6.2 Bn as of now and is expected to reach US$ 9.5 Bn by the year 2032 at a CAGR of 4.3% between 2022 and 2032.

Radiopharmaceuticals imply medications containing radioisotopes that could be used as both – therapeutic agents and diagnosis medications. Radiopharmaceuticals manage critical as well as chronic diseases. These days, various diagnostics are aimed towards organs with nuclear medicine radiopharmaceuticals.

PET and SPECT techniques are used in abundance while deploying radiopharmaceuticals. Some of the distinct features of radiopharmaceuticals include non-invasiveness, cost-effectiveness, easy of diagnosis, and higher sensitivity. Clinical applications include cardiology, oncology, lymphoma, and tumor.

Growing awareness regarding positive results provided by radiopharmaceuticals in checking chronic illness is one of the catalysts to radiopharmaceuticals market.

On the other hand, the fact that radiopharmaceuticals have half-life could restrain the market. It’s a known fact that radiopharmaceuticals involve higher investment. Short expectancy or half-life is one of the crucial factors restricting demand for radiopharmaceuticals. Thus, it’s only the developed regions who are able to increasingly adopt radiopharmaceuticals as of now. The developing economies still need to incorporate the technology to the fullest. Future Market Insights has walked through these functionalities with future prospects in its latest market study entitled ‘Radiopharmaceuticals Market’.

Key Takeaways from Radiopharmaceuticals Market

North America dominates the radiopharmaceuticals market due to rising frequency of cardiovascular diseases and cancer and the scenario is expected to persist even in the forecast period. Adopting innovative radioisotope production methods for treating chronic disorders is another reason.
Europe, led by the UK, is also expected to hold a significant market share due to the UK being subject to maximum incidences of cancer. Cancer Research UK estimate says that the UK alone houses 367,167 cancer patients.
The Asia-Pacific is poised to grow blatantly in the forecast period with it witnessing new product launches, collaborations, distribution agreements, acquisitions in an aplomb.

“The fact that radiopharmaceuticals are broadly used as biomarkers in molecular imaging is expected to take the radiopharmaceuticals market by storm in the upcoming period”, says an analyst from Future Market Insights.

Competitive Landscape

GE Healthcare inked an agreement with NorthStar Medical Radioisotopes, LLC for producing and distributing iodine-123 (I-123) capsules all across the US.
Bracco Diagnostics Inc., in March 2021, entered into partnership with CardioNavix, LLC for enhancing patients’ access to cardiac PET imaging. The new program is termed as ‘Bracco Mobile Isotope Service’, which ought to facilitate better patient care sites for providing cardiac PET imaging.
Jubilant Radiopharma, in August 2020, signed a MoU (Memorandum of Understanding) with Navidea Biopharmaceuticals, which focuses on an ELDA (Exclusive License and Distribution Agreement) for the latter’s diagnostic imaging agent called ‘Tilmanocept (technetium Tc 99m tilmanocept injection) in LATAM, Mexico, Canada, and the US.
Bayer AG, in June 2021, announced that it would acquire Noria Therapeutics Inc. along with PSMA Therapeutics Inc. with the objective of widening the former’s oncology portfolio that is into existence.
Norgine B.V., in March 2020, completed the acquisition of Azanta A/S, a specialty biopharmaceutical company. This included Nimorazole, a hypoxic radiosensitizer to treat cancer, and Angusta to facilitate labor induction.
Curium, in the year 2019, completed acquisition of MAP Medical, which would actually help it in strengthening the footprint all over the Europe with access to Baltic and Nordic countries.
The US FDA, in December 2020, completed approval of Gallium 68 PSMA-11 (Ga 68 PSMA-11). It holds the distinction of being the very first drug for PET imaging for diagnosing prostate cancer.

Top Radiopharmaceuticals companies : Siemens AG,Positron Corporation,Novartis (Advanced Accelerator Applications),Curium,GE Healthcare,Lantheus Holdings Inc.,Sotera Health LLC (Nordion Inc.),Bayer AG,Eckert Ziegler,

Key Segments Covered in the Radiopharmaceuticals Industry Analysis

Radiopharmaceuticals Market by Radioisotope Type: